Optimizing efficiency in relapsed or refractory multiple myeloma treatment in Greek National Health System hospitals: estimating the impact of using subcutaneous versus intravenous daratumumab

RESEARCH ARTICLE

Hippokratia 2024, 28(4): 158-164

Golnas P, Golna C, Kontogiorgos Y, Christodoulou T, Konstantopoulou T, Souliotis K
Health Policy Institute, Maroussi, Janssen Hellas, Pefki, Department of Social and Education Policy, University of Peloponnese, Corinth, Greece

Is SCUBE1 helpful to predict the arterial thrombotic risk in patients with multiple myeloma: a preliminary study

RESEARCH ARTICLE

Hippokratia 2019, 23(1): 21-24

Akdoğan E, Ayaz T, Kırbaş A, Rakıcı H
Department of Hematology, Department of Internal Medicine, Biochemist, Department of Gastroenterology, Recep Tayyip Erdogan University Medical Faculty, Research and Training Hospital, Rize, Turkey